Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.

Po-Yau HsuTzu-Sheng ChengShih-Chang ChuangWen-Tsan ChangPo-Cheng LiangCheng-Ting HsuYu-Ju WeiTyng-Yuan JangMing-Lun YehChing-I HuangYi-Hung LinChih-Wen WangMing-Yen HsiehNai-Jen HouMeng-Hsuan HsiehYi-Shan TsaiYu-Min KoChing-Chih LinKuan-Yu ChenChia-Yen DaiZu-Yau LinShinn-Cherng ChenJee-Fu HuangWan-Long ChuangChung-Feng HuangMing-Lung Yu

Published in: Cancer medicine (2021)

The results of this real-world study verified the tolerability and efficacy of regorafenib treatment for uHCC patients who failed prior sorafenib therapy, especially for those with lower baseline AFP levels or with early AFP response.

Keyphrases

metastatic colorectal cancer
open label
randomized controlled trial
squamous cell carcinoma
clinical trial
radiation therapy
liver metastases
mesenchymal stem cells
combination therapy
bone marrow
double blind